TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Healius Limited ( (AU:HLS) ) has issued an announcement.
Healius Limited has announced the appointment of Steven Rubic as a director, effective December 1, 2025. This appointment is accompanied by an initial interest notice, indicating Rubic’s holding of 30,000 fully paid ordinary shares in the company. This move is expected to strengthen the company’s governance and potentially impact its strategic direction, aligning with its growth objectives.
The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
More about Healius Limited
Healius Limited operates in the healthcare industry, providing medical and healthcare services. The company focuses on offering a range of diagnostic, imaging, and pathology services, catering to the needs of healthcare professionals and patients.
YTD Price Performance: -2.20%
Average Trading Volume: 2,741,680
Technical Sentiment Signal: Sell
Current Market Cap: A$711.6M
For a thorough assessment of HLS stock, go to TipRanks’ Stock Analysis page.